Activation of farnesoid X receptor induces RECK expression in mouse liver

Biochemical and Biophysical Research Communications

Volumn 443, Issue 1, 2014, Pages 211-216

  Peng, Xiaomin ^a   Wu, Weibin ^a   Zhu, Bo ^a   Sun, Zhichao ^a   Ji, Lingling ^a   Ruan, Yuanyuan ^a   Zhou, Meiling ^b   Zhou, Lei ^a   Gu, Jianxin ^a  

^a FUDAN UNIVERSITY   (China)

^b ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

Farnesoid X receptor; Primary hepatocytes; RECK; Transactivation

Indexed keywords

FARNESOID X RECEPTOR; MATRIX METALLOPROTEINASE; METHIONINE; RECK PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GLUCOSE METABOLISM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRON; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

MUS;

FARNESOID X RECEPTOR; FBS; FETAL BOVINE SERUM; FXR; MATRIX METALLOPROTEINASES; MCD; METHIONINE AND CHOLINE DEFICIENT; MMPS; PEPCK; PHOSPHOENOLPYRUVATE CARBOXYKINASE; PRIMARY HEPATOCYTES; RECK; RETINOID X RECEPTOR Α; REVERSION-INDUCING CYSTEINE RICH PROTEIN WITH KAZAL MOTIFS; RXRΑ; SHP; SMALL HETERODIMER PARTNER; SREBP-1C; STEROL REGULATORY ELEMENT-BINDING PROTEIN-1C; TRANSACTIVATION;

ANIMALS; CHLORINE; DIET; DOWN-REGULATION; GENE EXPRESSION REGULATION; GPI-LINKED PROTEINS; HEPATOCYTES; LIVER; MALE; METHIONINE; MICE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 84890859422     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.11.082     Document Type: Article

References (40)

1. Wang Y.D., Chen W.D., Huang W. FXR, a target for different diseases. Histol. Histopathol. 2008, 23:621-627.
2. Wang Y.D., Chen W.D., Moore D.D., Huang W. FXR: a metabolic regulator and cell protector. Cell Res. 2008, 18:1087-1095.
3. Forman B.M., Goode E., Chen J., Oro A.E., Bradley D.J., Perlmann T., Noonan D.J., Burka L.T., McMorris T., Lamph W.W., Evans R.M., Weinberger C. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 1995, 81:687-693.
4. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., Blumberg B., Kastner P., Mark M., Chambon P., Evans R.M. The nuclear receptor superfamily: the second decade. Cell 1995, 83:835-839.
5. Shulman A.I., Mangelsdorf D.J. Retinoid x receptor heterodimers in the metabolic syndrome. N. Engl. J. Med. 2005, 353:604-615.
6. Thomas A.M., Hart S.N., Kong B., Fang J., Zhong X.B., Guo G.L. Genome-wide tissue-specific farnesoid X receptor binding in mouse liver and intestine. Hepatology 2010, 51:1410-1419.
7. Goodwin B., Jones S.A., Price R.R., Watson M.A., McKee D.D., Moore L.B., Galardi C., Wilson J.G., Lewis M.C., Roth M.E., Maloney P.R., Willson T.M., Kliewer S.A. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell 2000, 6:517-526.
8. Watanabe M., Houten S.M., Wang L., Moschetta A., Mangelsdorf D.J., Heyman R.A., Moore D.D., Auwerx J. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J. Clin. Invest. 2004, 113:1408-1418.
9. Ma K., Saha P.K., Chan L., Moore D.D. Farnesoid X receptor is essential for normal glucose homeostasis. J. Clin. Invest. 2006, 116:1102-1109.
10. Sinal C.J., Tohkin M., Miyata M., Ward J.M., Lambert G., Gonzalez F.J. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000, 102:731-744.
11. Cariou B., van Harmelen K., Duran-Sandoval D., van Dijk T.H., Grefhorst A., Abdelkarim M., Caron S., Torpier G., Fruchart J.C., Gonzalez F.J., Kuipers F., Staels B. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J. Biol. Chem. 2006, 281:11039-11049.
12. Liu Y., Binz J., Numerick M.J., Dennis S., Luo G., Desai B., MacKenzie K.I., Mansfield T.A., Kliewer S.A., Goodwin B., Jones S.A. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J. Clin. Invest. 2003, 112:1678-1687.
13. Hartman H.B., Gardell S.J., Petucci C.J., Wang S., Krueger J.A., Evans M.J. Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice. J. Lipid Res. 2009, 50:1090-1100.
14. Fiorucci S., Rizzo G., Antonelli E., Renga B., Mencarelli A., Riccardi L., Orlandi S., Pruzanski M., Morelli A., Pellicciari R. A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J. Pharmacol. Exp. Ther. 2005, 314:584-595.
15. Zhang S., Wang J., Liu Q., Harnish D.C. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J. Hepatol. 2009, 51:380-388.
16. Takahashi C., Sheng Z., Horan T.P., Kitayama H., Maki M., Hitomi K., Kitaura Y., Takai S., Sasahara R.M., Horimoto A., Ikawa Y., Ratzkin B.J., Arakawa T., Noda M. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:13221-13226.
17. Oh J., Takahashi R., Kondo S., Mizoguchi A., Adachi E., Sasahara R.M., Nishimura S., Imamura Y., Kitayama H., Alexander D.B., Ide C., Horan T.P., Arakawa T., Yoshida H., Nishikawa S., Itoh Y., Seiki M., Itohara S., Takahashi C., Noda M. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 2001, 107:789-800.
18. Clark J.C., Thomas D.M., Choong P.F., Dass C.R. RECK - a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. Cancer Metastasis Rev. 2007, 26:675-683.
19. Sasahara R.M., Brochado S.M., Takahashi C., Oh J., Maria-Engler S.S., Granjeiro J.M., Noda M., Sogayar M.C. Transcriptional control of the RECK metastasis/angiogenesis suppressor gene. Cancer Detect. Prev. 2002, 26:435-443.
20. Lee K.J., Lee K.Y., Lee Y.M. Downregulation of a tumor suppressor RECK by hypoxia through recruitment of HDAC1 and HIF-1alpha to reverse HRE site in the promoter. Biochim. Biophys. Acta 1803, 2010:608-616.
21. Sun Z., Yu X., Wu W., Jia D., Chen Y., Ji L., Liu X., Peng X., Li Y., Yang L., Ruan Y., Gu J., Ren S., Zhang S. Fibroblast growth factor 7 inhibits cholesterol 7alpha-hydroxylase gene expression in hepatocytes. Biochem. Biophys. Res. Commun. 2012, 423:775-780.
22. Wu W., Sun Z., Wu J., Peng X., Gan H., Zhang C., Ji L., Xie J., Zhu H., Ren S., Gu J., Zhang S. Trihydrophobin 1 phosphorylation by c-Src regulates MAPK/ERK signaling and cell migration. PLoS ONE 2012, 7:e29920.
23. Huang L., Zhao A., Lew J.L., Zhang T., Hrywna Y., Thompson J.R., de Pedro N., Royo I., Blevins R.A., Pelaez F., Wright S.D., Cui J. Farnesoid X receptor activates transcription of the phospholipid pump MDR3. J. Biol. Chem. 2003, 278:51085-51090.
24. Flatt B., Martin R., Wang T.L., Mahaney P., Murphy B., Gu X.H., Foster P., Li J., Pircher P., Petrowski M., Schulman I., Westin S., Wrobel J., Yan G., Bischoff E., Daige C., Mohan R. Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR). J. Med. Chem. 2009, 52:904-907.
25. Maloney P.R., Parks D.J., Haffner C.D., Fivush A.M., Chandra G., Plunket K.D., Creech K.L., Moore L.B., Wilson J.G., Lewis M.C., Jones S.A., Willson T.M. Identification of a chemical tool for the orphan nuclear receptor FXR. J. Med. Chem. 2000, 43:2971-2974.
26. Edwards P.A., Kast H.R., Anisfeld A.M. BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. J. Lipid Res. 2002, 43:2-12.
27. Farrell G.C., Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006, 43:S99-S112.
28. Deng Y., Wang H., Lu Y., Liu S., Zhang Q., Huang J., Zhu R., Yang J., Zhang R., Zhang D., Shen W., Ning G., Yang Y. Identification of chemerin as a novel FXR target gene down-regulated in the progression of nonalcoholic steatohepatitis. Endocrinology 2013, 154:1794-1801.
29. Chen W.D., Wang Y.D., Zhang L., Shiah S., Wang M., Yang F., Yu D., Forman B.M., Huang W. Farnesoid X receptor alleviates age-related proliferation defects in regenerating mouse livers by activating forkhead box m1b transcription. Hepatology 2010, 51:953-962.
30. Xing X., Burgermeister E., Geisler F., Einwachter H., Fan L., Hiber M., Rauser S., Walch A., Rocken C., Ebeling M., Wright M.B., Schmid R.M., Ebert M.P. Hematopoietically expressed homeobox is a target gene of farnesoid X receptor in chenodeoxycholic acid-induced liver hypertrophy. Hepatology 2009, 49:979-988.
31. Song C.S., Echchgadda I., Baek B.S., Ahn S.C., Oh T., Roy A.K., Chatterjee B. Dehydroepiandrosterone sulfotransferase gene induction by bile acid activated farnesoid X receptor. J. Biol. Chem. 2001, 276:42549-42556.
32. Kast H.R., Goodwin B., Tarr P.T., Jones S.A., Anisfeld A.M., Stoltz C.M., Tontonoz P., Kliewer S., Willson T.M., Edwards P.A. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J. Biol. Chem. 2002, 277:2908-2915.
33. Anisfeld A.M., Kast-Woelbern H.R., Meyer M.E., Jones S.A., Zhang Y., Williams K.J., Willson T., Edwards P.A. Syndecan-1 expression is regulated in an isoform-specific manner by the farnesoid-X receptor. J. Biol. Chem. 2003, 278:20420-20428.
34. Chao F., Gong W., Zheng Y., Li Y., Huang G., Gao M., Li J., Kuruba R., Gao X., Li S., He F. Upregulation of scavenger receptor class B type I expression by activation of FXR in hepatocyte. Atherosclerosis 2010, 213:443-448.
35. Garcia-Ruiz I., de la Torre P., Diaz T., Esteban E., Fernandez I., Munoz-Yague T., Solis-Herruzo J.A. Sp1 and Sp3 transcription factors mediate malondialdehyde-induced collagen alpha 1(I) gene expression in cultured hepatic stellate cells. J. Biol. Chem. 2002, 277:30551-30558.
36. Rubio A., Guruceaga E., Vazquez-Chantada M., Sandoval J., Martinez-Cruz L.A., Segura V., Sevilla J.L., Podhorski A., Corrales F.J., Torres L., Rodriguez M., Aillet F., Ariz U., Arrieta F.M., Caballeria J., Martin-Duce A., Lu S.C., Martinez-Chantar M.L., Mato J.M. Identification of a gene-pathway associated with non-alcoholic steatohepatitis. J. Hepatol. 2007, 46:708-718.
37. Huang W., Ma K., Zhang J., Qatanani M., Cuvillier J., Liu J., Dong B., Huang X., Moore D.D. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science 2006, 312:233-236.
38. Yang F., Huang X., Yi T., Yen Y., Moore D.D., Huang W. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res. 2007, 67:863-867.
39. Tashiro K., Takai S., Jin D., Yamamoto H., Komeda K., Hayashi M., Tanaka K., Tanigawa N., Miyazaki M. Chymase inhibitor prevents the nonalcoholic steatohepatitis in hamsters fed a methionine- and choline-deficient diet. Hepatol. Res. 2010, 40:514-523.
40. Takagi S., Simizu S., Osada H. RECK negatively regulates matrix metalloproteinase-9 transcription. Cancer Res. 2009, 69:1502-1508.